NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.41B
This Quarter Return
-4.07%
1 Year Return
+32.9%
3 Year Return
+104.34%
5 Year Return
+145.08%
10 Year Return
+443.66%
AUM
$996M
AUM Growth
+$996M
(-2.4%)
Cap. Flow
+$58.7M
Cap. Flow
% of AUM
5.9%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
137
New
19
Increased
25
Reduced
38
Closed
13
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$27.4M |
| 2 |
Establishment Labs
ESTA
|
$24.9M |
| 3 |
Peloton Interactive
PTON
|
$15.6M |
| 4 |
Savara
SVRA
|
$13.9M |
| 5 |
The Bancorp
TBBK
|
$12.8M |
Top Sells
| 1 |
Pathward Financial
CASH
|
$27.2M |
| 2 |
Lyra Therapeutics
LYRA
|
$17.5M |
| 3 |
Red Violet
RDVT
|
$16.9M |
| 4 |
Dyne Therapeutics
DYN
|
$12.4M |
| 5 |
Golden Entertainment
GDEN
|
$9.92M |
Sector Composition
| 1 | Healthcare | 68.09% |
| 2 | Consumer Discretionary | 12.03% |
| 3 | Financials | 6.24% |
| 4 | Communication Services | 6.07% |
| 5 | Technology | 3.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
InspireMD
NSPR
$102M
| $5.06M | 0.3% | 2,026,600 -39,856 | -2% | -$99.5K |
|
|
AVDL
52
Avadel Pharmaceuticals
AVDL
$1.43B
| $4.92M | 0.29% | +350,000 | New | +$4.92M |
|
53
DXP Enterprises
DXPE
$1.96B
| $4.73M | 0.28% | 103,206 -166,600 | -62% | -$7.64M |
|
54
Neuropace
NPCE
$303M
| $4.66M | 0.27% | 616,823 -161,437 | -21% | -$1.22M |
|
55
Reading International Class A
RDI
$35.1M
| $4.61M | 0.27% | 3,244,573 -140,680 | -4% | -$200K |
|
56
Cellectar Biosciences
CLRB
$15.5M
| $4.58M | 0.27% | 1,833,325 -40,000 | -2% | -$100K |
|
57
Zynex
ZYXI
$49.7M
| $4.57M | 0.27% | 490,000 | – | – |
|
58
NN Inc
NNBR
$129M
| $4.37M | 0.26% | 1,456,446 +50,000 | +4% | +$150K |
|
59
DHI Group
DHX
$132M
| $4.32M | 0.25% | 2,066,417 +100,000 | +5% | +$209K |
|
60
Perella Weinberg Partners
PWP
$1.38B
| $4.31M | 0.25% | 265,474 +165,696 | +166% | +$2.69M |
|
|
CNTA
61
Centessa Pharmaceuticals
CNTA
$2.25B
| $4.06M | 0.24% | +450,000 | New | +$4.06M |
|
62
Gaia
GAIA
$143M
| $4.04M | 0.24% | 915,029 | – | – |
|
63
Context Therapeutics
CNTX
$75.4M
| $3.88M | 0.23% | +1,935,484 | New | +$3.88M |
|
64
Lexicon Pharmaceuticals
LXRX
$400M
| $3.87M | 0.23% | +2,304,150 | New | +$3.87M |
|
|
SLN
65
Silence Therapeutics
SLN
$227M
| $3.8M | 0.22% | 200,000 | – | – |
|
|
THTX
66
Theratechnologies
THTX
$149M
| $3.76M | 0.22% | 2,682,228 | – | – |
|
67
Enova International
ENVA
$3.03B
| $3.49M | 0.2% | 55,999 -15,866 | -22% | -$988K |
|
68
AYTU BioPharma
AYTU
$21.1M
| $3.17M | 0.19% | 1,086,812 | – | – |
|
|
BCOV
69
DELISTED
Brightcove, Inc.
BCOV
| $3.11M | 0.18% | +1,313,768 | New | +$3.11M |
|
70
Eton Pharmaceutcials
ETON
$464M
| $3.1M | 0.18% | +940,733 | New | +$3.1M |
|
71
Achieve Life Sciences
ACHV
$152M
| $3.07M | 0.18% | 654,000 | – | – |
|
72
DarioHealth
DRIO
$22.8M
| $2.85M | 0.17% | 2,391,325 -241,234 | -9% | -$287K |
|
73
Fossil Group
FOSL
$165M
| $2.7M | 0.16% | 1,905,278 +598,940 | +46% | +$848K |
|
74
Neurogene
NGNE
$264M
| $2.63M | 0.15% | 72,279 | – | – |
|
75
enVVeno Medical
NVNO
$15.4M
| $2.51M | 0.15% | 477,855 -17,881 | -4% | -$93.9K |
|